

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450



NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Tricia J. VOS, Michael PATANE, Michael E. SOLOMON, Christopher BLACKBURN and Mihaela D. DANCA

For: MODULATORS OF MELANOCORTIN RECEPTOR

1. Type of Application

This new application is for a(n)

- ☒ Original (nonprovisional)
- ☐ Design
- ☐ Plant
- ☐ Divisional.
- ☐ Continuation.
- ☐ Continuation-in-part (C-I-P).

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EL961947225US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature  
Sean Hunziker  
(type or print name of person certifying)

Date: December 4, 2003

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).  
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : **MPI02-196P1RNM**

**2. Benefit of Prior U.S. Application(s)** (35 U.S.C. Sections 119(e), 120, or 121)

- ☒ The new application being transmitted claims the benefit of prior U.S. Application Number 60/430,789 filed December 4, 2002.

**3. Maintenance of Copendency of Prior Application**

- A. ☐ Extension of time in prior application
- B. ☐ Conditional Petition for Extension of Time in Prior Application

*(complete this item, if previous item not applicable)*

- ☐ A conditional petition for extension of time is being filed in the pending **prior** application.
- ☐ A copy of the conditional petition filed in the prior application is attached.

**4. Abandonment of Prior Application** *(if applicable)*

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**Notification in Parent Application of This Filing**

- ☐ A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

**5. Papers Enclosed**

**Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

150 Pages of Specification, including  
109 Pages of Description  
40 Pages of Claims  
1 Page of Abstract  
0 Sheet of Drawings (Figure(s) 0 FIGURES)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
- ☐ Formal

**Practitioner's Docket No. : MPI02-196P1RNM**

☐ Informal

**6. Additional Papers Enclosed**

- ☐ Information Disclosure Statement (37 C.F.R. Section 1.98)
- ☐ Form PTO-1449 (PTO/SB/08A and 08B)
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☐ \_\_\_ pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), Diskette containing computer readable form of Sequence Listing (37 CFR Section 1.821(e) and 1.824), and \_\_\_ pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☐ Other:

**7. Declaration or Oath (including power of attorney)**

- ☒ ( 5 pages) An unexecuted Combined Declaration and Power of Attorney, which is enclosed.
- ☐ Not Enclosed.

**8. Assignment**

- ☒ An assignment of the invention to Millennium Pharmaceuticals, Inc. a copy of which
  - ☐ is enclosed.
  - ☒ will follow.

Practitioner's Docket No. : **MPI02-196P1RNM**

**9. Fee Calculation (37 C.F.R. Section 1.16)**

**A.**     ☒ Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	32	- 20 =	12	\$18.00	\$216.00
Independent Claims (37 C.F.R. Section 1.16(b))	2	- 3 =	0	\$86.00	\$00.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$290.00			\$00.00

**Filing Fee Calculation**

**\$986.00**

- ☐ Amendment canceling extra claims is enclosed.  
☐ Amendment deleting multiple-dependencies is enclosed.  
☐ Fee for extra claims is not being paid at this time.

**Practitioner's Docket N . : MPI02-196P1RNM**

**10. Method of Payment of Fees**

- ☐ Check in the amount of \$ \_\_\_\_\_.
- ☒ Charge Account No. 501668 in the amount of \$986.00  
A duplicate of this transmittal is attached.

**11. Authorization to Charge Additional Fees**

- ☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- ☒ 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- ☒ 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- ☐ 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☐ 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
- ☐ 37 C.F.R. Section 1.17 (application processing fees)
- ☐ 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

**12. Instructions as to Overpayment**

- ☒ Credit Account No. 501668.
- ☐ Refund

Practitioner's Docket Number: **MPI02-196P1RNM**

**13. Correspondence Address**

Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

December 4, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By *Ian Robert Silverman*

Ian Robert Silverman  
Registration No. 37,443  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-8604  
Facsimile - 617-551-8820

☒ **Statement Where No Further Pages Added**

☒ This transmittal ends with this page.